{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T13:52:56Z","timestamp":1777297976599,"version":"3.51.4"},"reference-count":26,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precision Oncology"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p> Within hematology and oncology, companion diagnostics (CDxs) play an increasing role in securing an optimal therapy for individual patients, and the US Food and Drug Administration (FDA) consider this type of assay essential for the safe and effective use of a corresponding therapeutic product. Most CDxs are developed prospectively using the drug-diagnostic codevelopment model, which normally secures the simultaneous approval of both drugs and diagnostics. A CDx assay is an important treatment decision tool that needs to be available simultaneously with the drug. However, within the past few years, several targeted drugs and new indications have been approved by the FDA without a CDx, despite the use of a predictive biomarker assay for patient selection during clinical development. A missing analytical and clinically validated CDx assay could affect the correct use of these drugs and ultimately patient safety. An alternative to FDA-approved or FDA-cleared CDxs could be to use a laboratory-developed test, which will normally miss documentation on the clinical validity. On the basis of the information available from different publicly available FDA databases, this article briefly discusses the issue of missing CDx assays in relation to the approval of hematological and oncological drugs and new indications. <\/jats:p>","DOI":"10.1200\/po.22.00100","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T19:59:30Z","timestamp":1655409570000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":8,"title":["Missing Companion Diagnostic for US Food and Drug Administration\u2013Approved Hematological and Oncological Drugs"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6255-0006","authenticated-orcid":false,"given":"Jan Tr\u00f8st","family":"J\u00f8rgensen","sequence":"first","affiliation":[{"name":"Medical Sciences, Dx-Rx Institute, Fredensborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0230"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.676939"},{"key":"b3","volume-title":"Table of Pharmacogenomic Biomarkers in Drug Labeling","author":"Food and Drug Administration","year":"2021"},{"key":"b4","volume-title":"List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)","author":"Food and Drug Administration","year":"2021"},{"key":"b5","volume-title":"Drugs@FDA: FDA-Approved Drugs","author":"Food and Drug Administration"},{"key":"b6","volume-title":"Postmarket Requirements and Commitments","author":"Food and Drug Administration"},{"key":"b7","volume-title":"Post-approval Studies (PAS) Database","author":"Food and Drug Administration"},{"key":"b8","volume-title":"Guidance for Industry and Food and Drug Administration Staff. In Vitro Companion Diagnostic Devices","author":"Food and Drug Administration","year":"2014"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.955"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2020.1711734"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3732"},{"key":"b12","volume-title":"Draft Guidance for Industry and Food and Drug Administration Staff. Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product","author":"Food and Drug Administration","year":"2016"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0758"},{"key":"b14","volume-title":"Full Prescribing Information for Rozlytrek (Entrectinib) Capsules, for Oral Use","author":"Food and Drug Administration","year":"2021"},{"key":"b15","volume-title":"Approval Letter for NDA 212726 Rozlytrek (Entrectinib)","author":"Food and Drug Administration","year":"2019"},{"key":"b16","volume-title":"Approval Letter for NDA 212725 Rozlytrek (Entrectinib)","author":"Food and Drug Administration","year":"2019"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0078-9"},{"key":"b18","volume-title":"Prescribing Full Information for Keytruda (Pembrolizumab) Injection, for Intravenous Use","author":"Food and Drug Administration","year":"2021"},{"key":"b19","volume-title":"Approval Letter for BLA 125514\/S-14 Pembrolizumab (Keytruda)","author":"Food and Drug Administration","year":"2017"},{"key":"b20","volume-title":"Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories on the Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)","author":"Food and Drug Administration","year":"2014"},{"key":"b21","volume-title":"The Changing Regulatory Landscape for Laboratory Developed Tests","author":"Robinson SA","year":"2021"},{"key":"b22","volume-title":"The Public Health Evidence for FDA Oversight of Laboratory Developed Tests: 20 Case Studies","author":"Food and Drug Administration","year":"2015"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqab164"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-021-01187-w"},{"key":"b25","volume-title":"Guidance for Industry Expedited Programs for Serious Conditions\u2014Drugs and Biologics Accelerated Approval Program","author":"Food and Drug Administration","year":"2014"},{"key":"b26","volume-title":"Guidance for Industry on Postmarketing Studies and Clinical Trials-Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act","author":"Federal Register"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO.22.00100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T20:00:01Z","timestamp":1655409601000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO.22.00100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1200\/PO.22.00100"],"URL":"https:\/\/doi.org\/10.1200\/po.22.00100","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"2022-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2200100"}}